Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- Japan Reform Minister Calls for Roadmap to Eliminate “Switch Lags” in 3 Years
December 12, 2023
- Ultragenyx’s Evinacumab, Alexion’s Danicopan in Line for Japan Approval
December 11, 2023
- Japan Panel OKs Basic Plan for Elective Care Scheme for LLPs; 900 APIs Targeted
December 11, 2023
- Will R&D Tax Credit Be Scaled Back with “Innovation Box” Rollout? Political Settlement Likely
December 8, 2023
- Sawai’s Revlimid Generic, BMS’ AG Now Available; Trerief AG Launch Set for Feb. 20
December 8, 2023
- Japan Diet Enacts Bill to Lift Ban on Cannabis-Derived Drugs
December 8, 2023
- First Generics for 5 APIs to Join NHI Price List; No Entries for Januvia, Zytiga
December 7, 2023
- JPWA Calls for Permanent Mechanism to Shore Up Drug Prices
December 7, 2023
- Pharma Industry Backs MHLW Proposal to Scrap PMP Indicators: Chuikyo Hearing
December 7, 2023
- CEFP Discusses Social Security Reform Timeline, No Surprises for Pharma Measures
December 6, 2023
- Authorized Generics Cannot be Regulated Now but Must Be Watched Closely: MHLW Panel Members
December 5, 2023
- 500 Billion Yen-Plus Annual Savings Expected from Generic Switches: Reiwa Rincho
December 5, 2023
- Japan Eyes Stronger OTC Sales Restrictions Due to Drug Abuse
December 4, 2023
- Reliance on Drug Price Cuts to Pool Financial Resources Must End: LDP Lawmakers
December 4, 2023
- Narrower Drug Price Gap Likely Due to Inflation, Efforts on Fair-Priced Distributions: Minister
December 4, 2023
- Proposed Introduction of Elective Care Scheme for LLP Copay “Hard to Understand”: Chuikyo Members
December 4, 2023
- Transitional Pneumovax Program for Age 70 and Up Set to End in March
December 4, 2023
- PMDA Reviewing Safety Risks for Carvykti, Keytruda, Tecentriq, and More
December 4, 2023
- Pharma Groups Lobby Firmly against Expansion of CEA Price Adjustments: LDP Hearing
December 4, 2023
- FY2023 Extra Budget Clears Diet, 1.4 Billion Yen to Boost Drug Production
December 1, 2023
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…